title: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.
abstract: BACKGROUND
  Previous results from our trial showed that adding oxaliplatin to radiotherapy (RT) increased survival in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) at 2 years. Here, we present the data of long-term efficacy and late toxic effects.
  
  
  METHODS
  Between January 2001 and January 2003, 115 Patients with nonkeratinizing/undifferentiated locoregionally advanced NPC were randomly to receive either RT alone (n = 56) or plus concurrent oxaliplatin 70 mg/m(2) weekly for six cycles (n = 59).
  
  
  RESULTS
  After a median follow-up of 114 months (range 18-139 months), the 5-year overall survival (OS) and metastasis-free survival (MFS) rates in the concurrent chemoradiotherapy (CCRT) group were significantly higher than those observed in the RT-alone group (OS, 73.2% versus 60.2%, P = 0.028; MFS, 74.7% versus 63.0%, P = 0.027). However, CCRT did not improve locoregional failure-free survival significantly. Subgroup analyses showed that the superiorities of CCRT mainly existed in the T3-4N0-1 stage subgroup (OS: HR = 0.394, P = 0.034). The grade 3/4 late toxic effects were similar in the two groups.
  
  
  CONCLUSIONS
  The long-term follow-up data confirms the role of CCRT as a treatment of locoregionally advanced NPC. Oxaliplatin can be considered as an alternative optional therapeutic regimen for these patients due to its high efficiency and low toxic effect.
authors: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.
authors: X
authors: X
authors: Wu
authors: P Y
authors: PY
authors: Huang
authors: P J
authors: PJ
authors: Peng
authors: L X
authors: LX
authors: Lu
authors: F
authors: F
authors: Han
authors: S X
authors: SX
authors: Wu
authors: X
authors: X
authors: Hou
authors: H Y
authors: HY
authors: Zhao
authors: Y
authors: Y
authors: Huang
authors: W F
authors: WF
authors: Fang
authors: Y Y
authors: YY
authors: Zhao
authors: C
authors: C
authors: Xue
authors: Z H
authors: ZH
authors: Hu
authors: J
authors: J
authors: Zhang
authors: J W
authors: JW
authors: Zhang
authors: Y X
authors: YX
authors: Ma
authors: W H
authors: WH
authors: Liang
authors: C
authors: C
authors: Zhao
authors: L
authors: L
authors: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D013534:Survival; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin
keywords: concurrent chemotherapy; nasopharyngeal carcinoma; oxaliplatin; radiotherapy